Selected stock price target news of the day - April 15th, 2025

By: Matthew Otto

Applied Digital Q3 FY2025 Results; Misses Revenue Estimates, Announces Strategic Shift

Applied Digital reported fiscal third-quarter 2025 revenue of $52.9 million, an increase of 22% year-over-year but below analyst expectations of $63.4 million. The shortfall was attributed to delayed renewals in its data center hosting segment, which saw revenue decline 7% to $35.2 million.

Cloud Services revenue grew by 220% year-over-year to $17.8 million, though it fell 36% sequentially due to a transition in contract structure and technical setbacks. Total operating costs reached $49.1 million, up 4% year-over-year, while selling, general, and administrative expenses fell 24% to $22.7 million.

Applied Digital posted a net loss attributable to common stockholders of $36.1 million, or $0.16 per share, widening 43% from the year-ago period. Adjusted net loss was $17.8 million, or $0.08 per share, beating the consensus estimate of a $0.11 loss. Adjusted EBITDA turned positive at $10.0 million compared to a loss of $1.3 million in the prior-year quarter.

Operationally, Applied Digital continues to advance its Ellendale HPC campus, with over 369,000 square feet of capacity under development. It is in discussions with hyperscalers to lease up to 400 MW of capacity across the site. Recent developments include a $375 million financing deal with Sumitomo Mitsui Banking Corporation. This also includes a potential $5 billion capital partnership with Macquarie Asset Management.

In line with its long-term goal of becoming a data center real estate investment trust (REIT), Applied Digital’s board approved plans to divest its Cloud Services segment. As of February 28, 2025, Applied Digital reported $261.2 million in cash and $689.1 million in debt.

Analysts Lower Price Targets Following Q3 Miss and Strategic Shift

Needham analyst John Todaro maintained a Buy rating but trimmed the price target from $11 to $10.
HC Wainwright & Co. analyst Kevin Dede reiterated a Buy rating while slashing the price target from $12 to $7.
Cantor Fitzgerald analyst Brett Knoblauch reduced his price target from $14 to $7.
Craig-Hallum analyst George Sutton lowered the price target to $10.

Which Analyst has the best track record to show on APLD?

Analyst John Todaro (NEEDHAM) currently has the highest performing score on APLD with 3/19 (15.79%) price target fulfillment ratio. His price targets carry an average of $0.35 (3.29%) potential upside. Applied Digital stock price reaches these price targets on average within 34 days.

ADM Scales Back China Trading Operations Amid Profit Decline and Global Restructuring

Archer-Daniels-Midland (ADM) is shutting down its domestic trading operations in China and laying off staff within its Agricultural Services and Oilseeds segment. The move is part of a broader global cost-cutting initiative aimed at reducing expenses by $500 million to $700 million over the next three to five years.

While ADM did not disclose specific layoff figures, a source indicated that between 40 and 50 employees would be affected in China, with approximately 30 roles eliminated at its Toepfer Shanghai subsidiary starting this week. Only around 10 employees are expected to remain in the Shanghai office. ADM said the phase-out of domestic trading operations at Toepfer Shanghai would be completed by the end of September 2025.

ADM’s decision follows a 40% year-over-year decline in operating profit in its Agricultural Services and Oilseeds division in 2023. It also reported its lowest fourth-quarter adjusted earnings in six years, with Q4 adjusted earnings per share falling to $0.93, compared to $1.93 in the prior-year quarter. Revenue for 2023 dropped to $85.25 billion, down from $101.56 billion in 2022.

Analysts Update Ratings Amid Trading Exit and Restructuring

Citigroup analyst Thomas Palmer maintained a Neutral rating, while reducing the price target from $51 to $49.
BofA Securities analyst Steve Byrne upgraded to Neutral rating.

Which Analyst has the best track record to show on ADM?

Analyst Vincent Andrews (MORGAN STANLEY) currently has the highest performing score on ADM with 6/8 (75%) price target fulfillment ratio. His price targets carry an average of $0.56 (1.21%) potential upside. Archer-Daniels-Midland stock price reaches these price targets on average within 170 days.

VERVE-102 Shows Initial Safety and Efficacy in Lowering LDL Cholesterol in Early-Stage Clinical Trial

Verve Therapeutics has shared early results from its Heart-2 Phase 1b clinical trial, testing a new one-time gene editing treatment called VERVE-102. The treatment is designed for people with a genetic condition called heterozygous familial hypercholesterolemia (HeFH) or those with early heart disease. These individuals often struggle with dangerously high levels of LDL cholesterol (commonly called “bad cholesterol”), even when using current medications.

Around 31 million adults in the U.S. have high LDL cholesterol, and more than 1.3 million are estimated to have HeFH. VERVE-102 is designed to permanently switch off the PCSK9 gene in the liver—the gene responsible for keeping LDL-C levels high—with a single IV infusion.

So far, 14 patients have received the treatment at three different dose levels. At the highest tested dose, participants saw their LDL-C drop by an average of 53%, with the biggest drop being 69%. Importantly, all three people who received the highest amount of RNA (over 50 mg) had LDL-C reductions of over 50%. No serious side effects linked to the treatment were observed, and the most common issue—a mild reaction to the infusion—went away quickly with standard medication.

Analysts Adjust Ratings and Price Targets Following Positive Trial Data

JPMorgan analyst Eric Joseph lowered the price target from $18 to $16.
Cantor Fitzgerald analyst Rick Bienkowski upgraded from Neutral to Overweight.
Guggenheim analyst Etzer Darout maintained a Buy rating and increased the price target from $18 to $24.
Canaccord Genuity analyst Whitney Ijem maintained a Buy rating, while raising the price target from $32 to $39.

Which Analyst has the best track record to show on VERV?

Analyst Eric Joseph (JPMORGAN) currently has the highest performing score on VERV with 1/2 (50%) price target fulfillment ratio. His price targets carry an average of $6.46 (36.83%) potential upside. Verve Therapeutics stock price reaches these price targets on average within 1 days.